visceral adipose tissue is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-25. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.
Quantitation of the peptide relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection, typically at 214 nanometers, where the peptide bond absorbs. Identity is confirmed by mass spectrometry, most often electrospray ionization coupled to liquid chromatography, and by peptide mapping after enzymatic digestion. Because related impurities differ only slightly in sequence or modification, method development emphasizes resolution rather than speed. Purity is usually reported as a percentage of the main peak area, with individual impurities listed separately when they exceed a defined reporting threshold.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
Lyophilized tesamorelin is generally stored refrigerated at temperatures between 2 and 8 degrees Celsius. The solid form is comparatively stable when kept dry and protected from light. Moisture uptake can promote aggregation and degradation, so sealed containers with desiccant are common. Researchers typically avoid repeated temperature cycling, which may stress the peptide. Documentation accompanying reference materials usually specifies a shelf life under these conditions.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
== Equipment == The facility has a custom-made 3 mega-volt tandem accelerator mass spectrometer. It also has a 200 sample ion source, a high resolution, 120° injection magnet, a 90° high energy analysis magnet (mass-energy product 350 MeV-AMU), a 65°, 1.7 m radius electric analyzer and a 2 channel gas ionization detector. The spectrometer weighs around 44 tons and is around 25 metres long. The facility can be seen through a two-storey window in the lobby of the Advanced Research Complex. The spectrometer accelerates the isotopes to a very high speed with almost no contamination, thus allowing for the detection of trace isotopes at very low levels.
=== Location === The SA node is located in the wall (epicardium) of the right atrium, laterally to the entrance of the superior vena cava in a region called the sinus venarum (hence sino- + atrial). It is positioned roughly between a groove called the crista terminalis located on the internal surface of the heart and the corresponding sulcus terminalis, on the external surface. These grooves run between the entrance of the superior vena cava and the inferior vena cava.
Multiple testing was done to be able to narrow down whether his form of Syncope is caused by mental factors or cardiac abnormalities, the results are still pending. Dr. Lisa Sanders took Matt’s story to the column and awaited for responses from the audience with ideas. Out of the hundreds of responses, only two were the most cohesive towards Matt’s symptoms. The first possibility was Vasovagal Syncope, where the nervous system will send an incorrect message too slow down the heart and can cause it to stop, the tilt table test performed on Matt could provide a definitive answer to this theory. The second possibility is Temporal lobe epilepsy which is a kind of seizure that is correlated to a sense of “strange” thoughts, feelings, or sense of Deja Vu. Matt was subjected to an EEG which did not show any preliminary seizure disorders, however the specialist who reviewed his results noted that the EEG might not express any deep temporal lobe seizures. The tilt table test performed on Matt came back negative for Vasovagal Syncope, however Matt was fitted with a heart tracker to be able to detect any abnormal signals within the heart during an episode. Matt finally had an episode with his heart loop tracker, the tracker was able to detect a 6 second heart stop during his episode. On the same day Matt had this episode he had another one once his stress level started to rise, this was the first time in the entire duration of his illness that he's had two episodes in one day. Dr.
Compared to the Basic Test it is more sensitive to operator technique, and as a result may be less precise. Acute Toxicity Solid-Phase Test is a procedure that allows the test organism to come in direct contact with the solid sample as particulate in an aqueous suspension. Normally, this test provides results indicating equal or higher toxicity when compared to eluate or pore water tests of the same sample. This is due to either equal or increased bioavailability resulting from direct contact. This test is subject to several sources of interference of luminescence including loss of bacteria from effects other than toxicity such as filtration of the sample; absorption of light due to color; and scattering of light due to turbidity. Corrections can be made by testing a sample of similar particle composition that is known to not be toxic. This test consists of two controls and 13 sample dilutions in duplicate. The Solid-Phase Test exposes the bacteria in such a way that is not always possible with pore water and elutriate. Acute Toxicity Comparison & Inhibition Tests are the best procedures for testing samples with a low level of toxicity when an ECxx can not be determined using the Basic Test. These protocols are recommended for testing waste water treatment plant effluent, stormwater runoff, drinking water, pore water, and eluate. These tests use multiple replicates of a sample at a single concentration. Similar to the Basic Test, the Comparison Test protocol uses zero time light readings used for correcting the timed light level readings.
Sources: en.wikipedia.org
=== Pregnancy === Based on the limited data available, docetaxel appears to be safe in pregnancy if administered during the second and third trimesters; however, maternal and fetal risks should be weighed against benefits to determine the appropriate course of action. As with all chemotherapeutic agents, docetaxel administered to pregnant animals causes a variety of embryofetal toxicities, including death, when given during the period of organogenesis. Yet adequate studies investigating maternal and fetal effects in humans are lacking. One small systematic review that examined the use of taxanes to treat breast cancer in pregnancy showed that, out of 19 patients, only three congenital malformations occurred. Two cases of cerebral ventriculomegaly observed in the study were documented prior to the administration of chemotherapy, suggesting an alternate cause of congenital malformation. The third case involved pyloric stenosis in an infant whose mother received a combination regimen of docetaxel, doxorubicin, cyclophosphamide and paclitaxel; because the fetus was exposed to multiple drugs in utero, it remains difficult to identify docetaxel as the causative teratogenic agent. Further studies are needed to better assess the safety of docetaxel in pregnancy and determine appropriate dosing in pregnant women.
The goal of substituting DNA by XNA may also be reached by another route, namely by engineering the environment instead of the genetic modules. This approach has been successfully demonstrated by Marlière and Mutzel with the production of an E. coli strain whose DNA is composed of standard A, C and G nucleotides but has the synthetic thymine analogue 5-chlorouracil instead of thymine (T) in the corresponding positions of the sequence. These cells are then dependent on externally supplied 5-chlorouracil for growth, but otherwise they look and behave as normal E. coli. These cells, however, are currently not yet fully auxotrophic for the Xeno-base since they are still growing on thymine when this is supplied to the medium.
As Colin Bundy observed, the establishment of local councils "succeeded in transforming aloof, physically distant agents of the state into identifiable individuals who lived and operated among those whom they ruled", and who could therefore become the focal point for residents' anger.
micronucleus The smaller of the two types of nuclei that occur in pairs in the cells of some ciliated protozoa. Whereas the larger macronucleus is polyploid, the micronucleus is diploid and generally transcriptionally inactive except for the purpose of sexual reproduction, where it has important functions during conjugation.
Obesity increases the risk of many physical and mental conditions. These comorbidities are most commonly shown in metabolic syndrome, a combination of medical disorders which includes: diabetes mellitus type 2, high blood pressure, high blood cholesterol, and high triglyceride levels. The CDC has found that obesity is the single strongest risk factor for severe COVID-19 illness. Complications may be either directly caused by obesity or indirectly related through mechanisms sharing a common cause such as a poor diet or a sedentary lifestyle. The strength of the link between obesity and specific conditions varies. One of the strongest is the link with type 2 diabetes. Excess body fat underlies 64% of cases of diabetes in men and 77% of cases in women. Health consequences fall into two broad categories: those attributable to the effects of increased fat mass (such as osteoarthritis, obstructive sleep apnea, social stigmatization) and those due to the increased number of fat cells (diabetes, cancer, cardiovascular disease, non-alcoholic fatty liver disease). Increases in body fat alter the body's response to insulin, potentially leading to insulin resistance. Increased fat also creates a proinflammatory state, and a prothrombotic state.
Sources: en.wikipedia.org
==== 9 April ==== Hezbollah said that it had halted attacks on Israel and on Israeli soldiers in Lebanon. However, in the early hours of the day, it claimed responsibility for a rocket attack on northern Israel, stating that attacks would continue until Israel stopped striking Lebanese territories, regardless of the ceasefire. Hezbollah struck Kiryat Shmona, Taibe, and Manara. Despite the agreement to open the Strait of Hormuz, it remains "effectively closed", with Iran limiting the number of ships that can cross and charging tolls of over $1 million per ship, or even $1 million per barrel. Only four ships carrying dry cargo (and thus not oil or gas tankers) managed to pass through Hormuz on the first day of the truce, with the daily average being of nine ships during the war. Drones attacked vital infrastructure in Kuwait, prompting the country to respond by fending them off.
Do6a is a venom peptide found in the venom of the Velvet ant (Mutillidae). It targets Pickpocket/Balboa ion channels in class IV dendritic arborizing (cIV da) neurons in larvae of fruit flies (Drosophila melanogaster). Do6a has been shown to also activate nociceptors in praying mantis (Mantodea).
In September 2014, the company acquired Innopharma for $225 million, plus up to $135 million in milestone payments, in a deal that expanded Pfizer's range of generic and injectable drugs. On January 5, 2015, the company announced it would acquire a controlling interest in Redvax, expanding its vaccine portfolio targeting human cytomegalovirus. In February 2015, the company received approval from the Food and Drug Administration for palbociclib (Ibrance) for treatment of certain types of breast cancer. In March 2015, the company announced it would restart its collaboration with Eli Lilly and Company surrounding the Phase III trial of Tanezumab. In May 2015, Pfizer and a Bar-Ilan University laboratory announced a partnership based on the development of medical DNA nanotechnology. In June 2015, the company acquired Nimenrix and Mencevax, meningococcal vaccines, from GlaxoSmithKline for around $130 million. In September 2015, Pfizer acquired Hospira for $17 billion, including the assumption of debt. Hospira was the largest producer of generic injectable pharmaceuticals in the world. On November 23, 2015, Pfizer and Allergan announced a planned $160 billion merger, in the largest pharmaceutical deal ever and the third largest corporate merger in history. The proposed transaction contemplated that the merged company maintain Allergan's Republic of Ireland domicile, resulting in the new company being subject to corporation tax at the relatively low rate of 12.5%.
Other techniques (such as X-rays, CAT scans, PET scans or NMR) are used to produce images of internal abnormalities resulting from the growth of an infectious agent. The images are useful in detection of, for example, a bone abscess or a spongiform encephalopathy produced by a prion. The benefits of identification, however, are often greatly outweighed by the cost, as often there is no specific treatment, the cause is obvious, or the outcome of an infection is likely to be benign.
Substitution reactions that proceed through a free carbocation intermediate, such as unimolecular substitution reactions, lead to non-stereospecific addition of substituents which results in racemization. Although unimolecular elimination reactions also proceed through a carbocation, they do not result in a chiral center. They result instead in a set of geometric isomers in which trans/cis (E/Z) forms are produced, rather than racemates. In a unimolecular aliphatic electrophilic substitution reaction, if the carbanion is planar or if it cannot maintain a pyramidal structure, then racemization should occur, though not always. In a radical-substitution reaction, if the formation of the free radical takes place at a chiral carbon, then racemization is almost always observed. The rate of racemization (from L-forms to a mixture of L-forms and D-forms) is used as a way of dating biological samples in tissues with slow rates of turnover, forensic samples, and fossils in geological deposits. This technique is known as amino acid dating.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.